Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multi-Center, Open-Label, Non-Randomized Study of Intravenous RPR109881 Given Every 3 Weeks in Patients With Metastatic Breast Cancer Progressing After Therapy With Anthracyclines, Taxanes and Capecitabine

NCT00087958 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00087958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00087958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multi-Center, Open-Label, Non-Randomized Study of Intravenous RPR109881 Given Every 3 Weeks in Patients With Metastatic Breast Cancer Progressing After Therapy With Anthracyclines, Taxanes and Capecitabine
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2004
Completion date
April 30, 2009
Enrollment
168 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer